Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 8213 results

  1. High resolution anoscopy and laser therapy for intraepithelial neoplasia of the anus in high risk or immunocompromised patients

    Topic prioritisation

  2. Multi-vessel minimal access coronary artery surgery for multi-vessel coronary artery disease

    Topic prioritisation

  3. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC

  4. XVIVO hypothermic perfusion of the DCD heart

    Topic prioritisation

  5. Botulinum injection of abdominal wall prior to massive incisional hernia repair

    Topic prioritisation

  6. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

  7. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development Reference number: GID-TA11199 Expected publication date: TBC

  8. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    In development Reference number: GID-TA11425 Expected publication date: TBC

  9. Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

  10. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

  11. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

  12. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

  13. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

  14. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation